Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 29 of 370
Next
>>
>
701 to 725 of 9248 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Antibody	Perturbagen Target	Perturbagen Class	Biological Replicate ID	Conc Unit	GR50	GEC50	GRmax	GRinf	GR Hill Coefficient	GR_AOC	GR r2	Nominal Division Rate
BT-20	TNBC	Basal A	Omipalisib		PI3K	PI3K	5904.087	uM	0.01677	0.05419	-0.7359	-0.6548	0.7136	0.8200	0.9902	1.2506
BT-20	TNBC	Basal A	Oxamflatin		HDAC	HDAC	10581.147	uM	3.3170	8.41640	-0.8647	-1.0000	1.1799	0.3154	0.9938	1.0319
BT-20	TNBC	Basal A	Oxamflatin		HDAC	HDAC	11854.147	uM	4.3630	11.66910	-0.7642	-1.0000	1.1167	0.2986	0.9969	1.2634
BT-20	TNBC	Basal A	PD 98059		MEK	MAPK	11854.159	uM	inf	4.93760	0.5163	0.5481	4.9992	0.1332	0.8842	1.2639
BT-20	TNBC	Basal A	PD 98059		MEK	MAPK	10581.136	uM	11.75260	28.55490	-0.1372	-0.5462	0.8317	0.2454	0.9320	0.8342
BT-20	TNBC	Basal A	PD173074		FGFR1/3	RTK	5904.1	uM	17.11780	21.10880	-0.8704	-0.8775	4.8358	0.1699	0.9880	1.3369
BT-20	TNBC	Basal A	PD173074		FGFR1/3	RTK	10385.093	uM	7.40180	8.70540	-0.6094	-0.6116	4.9251	0.1150	0.9928	0.6082
BT-20	TNBC	Basal A	PD184352		MEK	MAPK	11854.155	uM	inf	inf	0.7890	0.7890	0.0000	0.0854	-0.0152	1.3396
BT-20	TNBC	Basal A	PD184352		MEK	MAPK	11854.155	uM	inf	inf	0.7890	0.7890	0.0000	0.0854	-0.0152	1.3396
BT-20	TNBC	Basal A	PD184352		MEK	MAPK	10581.146	uM	inf	inf	0.7166	0.7166	0.0000	0.1279	0.5419	1.1650
BT-20	TNBC	Basal A	PD184352		MEK	MAPK	10581.146	uM	inf	inf	0.7166	0.7166	0.0000	0.1279	0.5419	1.1650
BT-20	TNBC	Basal A	Pemetrexed		TYMS/DHFR/GARFT	TYMS	10385.095	uM	inf	inf	1.0500	1.0500	0.0000	0.0010	0.0617	0.7986
BT-20	TNBC	Basal A	Pemetrexed		TYMS/DHFR/GARFT	TYMS	5902.095	uM	inf	inf	1.0500	1.0500	0.0000	-0.0500	-inf	1.0245
BT-20	TNBC	Basal A	Pemetrexed		TYMS/DHFR/GARFT	TYMS	5904.095	uM	inf	inf	1.0500	1.0500	0.0000	-0.0500	-inf	0.6537
BT-20	TNBC	Basal A		Pertuzumab			5903.102	mg/ml	inf	inf	0.9324	0.9324	0.0000	-0.0074	-0.0405	1.2557
BT-20	TNBC	Basal A	PS-1145		IKK	NFKB	10385.065	uM	inf	inf	0.4664	0.4664	0.0000	0.3016	0.3040	0.6599
BT-20	TNBC	Basal A	PS-1145		IKK	NFKB	5902.065	uM	inf	inf	0.7265	0.7265	0.0000	0.1074	0.4823	1.2690
BT-20	TNBC	Basal A	PS-1145		IKK	NFKB	5904.065	uM	inf	inf	0.7615	0.7615	0.0000	0.0871	0.5385	1.1681
BT-20	TNBC	Basal A	Purvalanol A		CDK1	CDK	5904.067	uM	inf	45.30240	0.5599	0.5592	4.9391	0.0052	0.9332	1.0398
BT-20	TNBC	Basal A	Purvalanol A		CDK1	CDK	5903.067	uM	24.62630	22.18010	0.1126	0.1005	2.1444	0.1732	0.9728	1.2584
BT-20	TNBC	Basal A	Purvalanol A		CDK1	CDK	5902.067	uM	22.26720	24.98750	-0.3894	-0.3897	5.0000	0.2005	0.9961	1.1750
BT-20	TNBC	Basal A	QNZ		NFkB	NFKB	5904.096	uM	inf	0.23708	0.5049	0.5398	1.7167	0.1665	0.9717	0.9724
BT-20	TNBC	Basal A	Ribavirin				15385.211	uM	inf	inf	0.4315	0.4315	0.0000	0.1628	0.4682	0.7321
BT-20	TNBC	Basal A	Ro 32-0432		PKC	PKC	10581.142	uM	inf	inf	1.0451	1.0451	0.0000	0.0021	-0.0023	0.7885
BT-20	TNBC	Basal A	SB-3CT		MMP2/9	MMP	10581.144	uM	inf	inf	0.7913	0.7913	0.0000	0.1321	0.3363	1.2048

|<
<<
Previous
Page 29 of 370
Next
>>
>
701 to 725 of 9248 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)